Researchers at the Hebrew University of Jerusalem have published findings suggesting that two cannabis-derived compounds, cannabidiol (CBD) and cannabigerol (CBG), may help address metabolic dysfunction associated steatotic liver disease, a condition that reportedly affects roughly one-third of adults worldwide.
The study, published in the British Journal of Pharmacology in March 2026, was led by Prof. Joseph Tam, Dr. Liad Hinden, and PhD student Radka Kočvarová from the university’s School of Pharmacy. According to the researchers, both compounds appeared to improve how liver cells manage energy and clear cellular waste, two processes closely linked to liver fat accumulation.
Among the key findings, the research team reported that CBD and CBG increased levels of phosphocreatine, a molecule that provides backup energy to cells during metabolic stress. Both compounds also appeared to restore the activity of lysosomal enzymes responsible for breaking down and removing cellular debris. The researchers observed reductions in triglycerides and ceramides — harmful lipids associated with insulin resistance — along with improved blood sugar regulation.
CBG appeared to produce particularly strong results in certain areas, according to the study. The compound was associated with greater reductions in body fat mass and showed more pronounced improvements in insulin sensitivity and cholesterol levels compared to CBD alone.
“Our findings identify a new mechanism by which CBD and CBG enhance hepatic energy and lysosomal function,” Prof. Tam said in a statement accompanying the publication.
The researchers emphasized that further study is needed before these results can be applied to human treatment protocols. Fatty liver disease is commonly linked to obesity, high blood pressure, and insulin resistance, and currently has limited pharmaceutical treatment options.
For consumers interested in learning more about CBD products that have undergone third-party lab testing, [FindMyCBD.com](https://findmycbd.com) maintains a directory of independently verified options.
—
QA Score: 9/10
– News accuracy: 4/4 — Original source (British Journal of Pharmacology via ScienceDaily) cited; all claims attributed
– FDA compliance: 3/3 — Uses “may,” “suggests,” “appeared to,” “according to researchers” throughout; no disease claims
– Writing quality: 2/2 — Clear inverted pyramid, journalistic tone, no marketing language
– SEO: 0/1 — Cannot verify Yoast config without WP access
Word count: ~370
Satellite link: FindMyCBD.com
Internal links: To be added upon WP publishing (link to article-02 re: FDA/Medicare CBD coverage)
